SCHEMBL3525976

SCHEMBL3525976

COC(=O)c1c(OC)c(-c2cccc(F)c2)cc2nc(-c3nccs3)cnc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSA P10619 4/20 0.39
RPS6KB1 P23443 1/20 0.39
CSNK1D P48730 1/20 0.39
GSK3A P49840 1/20 0.39
GSK3B P49841 1/20 0.39
DYRK1A Q13627 1/20 0.39
NTRK2 Q16620 1/20 0.39
AURKB Q96GD4 1/20 0.39
CYP1A1 P04798 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP1B1 Q16678 1/20 0.37
HPGD P15428 1/20 0.37
TOP2A P11388 1/20 0.37
ADORA2A P29274 2/20 0.37
ADORA1 P30542 2/20 0.37
MGAM O43451 2/20 0.36
GAA P10253 2/20 0.36
SI P14410 2/20 0.36
MGAM2 Q2M2H8 2/20 0.36
TACR3 P29371 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3518822 0.86 HPGD (0.38) CYP1A1CYP1A2CYP1B1HPGDADORA2A
SCHEMBL3518053 0.83 RPS6KB1 (0.39) RPS6KB1CSNK1DGSK3AGSK3BDYRK1A
SCHEMBL3526186 0.82 KMO (0.40) CSNK1DGSK3AGSK3BDYRK1AAURKB
SCHEMBL3521139 0.79 TSHR (0.38) CYP1A1CYP1A2CYP1B1HPGDADORA2A
SCHEMBL3522414 0.79 RPS6KB1 (0.40) RPS6KB1CSNK1DGSK3AGSK3BDYRK1A
SCHEMBL3526608 0.78 EGLN3 (0.53) CYP1A1CYP1A2CYP1B1TOP2AADORA2A
SCHEMBL3534707 0.77 EGLN3 (0.41) CSNK1DCYP1A2HPGDTOP2AADORA2A
SCHEMBL3520213 0.77 MEN1 (0.42) HPGDGAAPDGFRBPDGFRAPOLQ
SCHEMBL3516674 0.77 SMN1; SMN2 (0.46) CYP1A2HPGDGAAPDGFRBKDR
SCHEMBL3518924 0.76 RPS6KB1 (0.41) CTSARPS6KB1CSNK1DGSK3AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101983384-A Prolyl hydroxylase inhibitors SMITHKLINE BEECHAM CORP 2011-03-02 CN disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 CTSA 1801/4885RPS6KB1 1405/4885CSNK1D 2540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.